R & D Daily: AstraZeneca imfinzi combination therapy is qualified to treat liver cancer orphans
-
Last Update: 2020-01-21
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Revolution plans to develop a new type of small molecule inhibitor; Hongyun Huaning new drug gma301 is approved for clinical application in China; RNA vaccine makes claudin car-t cells more effective against solid tumors We focus on the latest development of pharmaceutical research and development, and provide timely and accurate information reference for R & D personnel Recently, revolution medicine announced that it plans to raise $100 million in IPO to develop new small molecule inhibitors for cancer treatment Imfinzi (durvalumab) and tremelimumab have been awarded the orphan drug qualification for the treatment of HCC by the US FDA, AstraZeneca announced Tuesday Recently, gma301, a new humanized monoclonal antibody developed by Hongyun Huaning, has been approved for clinical trial in China and is used for the treatment of pulmonary hypertension.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
